- A next-generation genetic medicine platform built on proprietary ionizable lipids, leveraging novel chemical space and high-throughput discovery to enable precise RNA delivery and selective targeting of extrahepatic tissues beyond the liver.
- Demonstrated platform versatility with lead programs achieving both in vivo CD8+ CAR-T generation driving deep B-cell depletion, and efficient renal gene editing through selective LNP tropism.
CAMBRIDGE, Mass. & PHILADELPHIA, Pa. – May 6, 2026 – Nava Therapeutics, a biotechnology company developing a new class of genetic medicines through precision RNA delivery, today announced that Ali Nahvi, Ph.D., Chief Technology Officer, will present preclinical data on the company’s lipid nanoparticle (LNP) delivery platform at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics, taking place May 11-14, 2026, at the Hynes Convention Center in Boston.
Dr. Nahvi’s presentation will focus on how Nava’s modular LNP platform enables functional delivery of nucleic acids to extrahepatic cell types, including immune cells and kidney. The presentation will showcase preclinical data demonstrating in vivo generation of functional CD8+ CAR-T cells and efficient renal gene editing driven by distinct and selective LNP tropism.
“Effective delivery of genetic medicines to tissues outside the liver remains a central challenge in the field of genetic medicine,” said Dr. Nahvi. “By overcoming these delivery barriers, we can unlock new therapeutic possibilities for patients with autoimmune diseases, chronic kidney disease, and other conditions where genetic medicines can make a meaningful difference.”
Nava’s platform is built on proprietary ionizable lipids that exploit novel chemical space to achieve precise targeting of previously inaccessible extrahepatic tissues. The company’s in vivo CAR-T program has demonstrated deep B-cell depletion in preclinical models with favorable tolerability, while its kidney-tropic LNP platform has achieved efficient editing across multiple kidney compartments and cell types, including disease-relevant podocytes and proximal tubule cells. Through rational design and targeted exploration, Nava has developed proprietary LNPs with enhanced potency, favorable tolerability, and scalable manufacturability.
Presentation Title: In Vivo Generation of Functional CD8+ CAR T-Cells and Renal Gene Editing Driven by Distinct and Selective LNP Tropism
Track: Delivery of Macromolecules
Session Type: Oral
Date and Time: Tuesday, May 13 at 3:00 p.m. ET
Location: Hynes Convention Center, Boston, MA
About Nava Therapeutics
Nava Therapeutics is a biotechnology company developing a new generation of genetic medicines through precision RNA delivery. By combining rational lipid design with high-throughput discovery, Nava has built a proprietary LNP platform capable of selectively targeting cells and tissues beyond the liver.
Business Development contact
For partnership, licensing, or collaboration inquiries, please reach out to bd@navatx.com.
General Inquiries contact
For all other inquiries, please reach out to info@navatx.com.